DE60126801D1 - Lipidformulierungen zur zielgerichteten abgabe - Google Patents

Lipidformulierungen zur zielgerichteten abgabe

Info

Publication number
DE60126801D1
DE60126801D1 DE60126801T DE60126801T DE60126801D1 DE 60126801 D1 DE60126801 D1 DE 60126801D1 DE 60126801 T DE60126801 T DE 60126801T DE 60126801 T DE60126801 T DE 60126801T DE 60126801 D1 DE60126801 D1 DE 60126801D1
Authority
DE
Germany
Prior art keywords
targeted delivery
lipid formulations
lipid
active agent
systemic delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126801T
Other languages
English (en)
Other versions
DE60126801T2 (de
Inventor
R Cullis
R Maclachlan
R Fenske
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Inex Pharmaceuticals Corp
Original Assignee
University of British Columbia
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Inex Pharmaceuticals Corp filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60126801D1 publication Critical patent/DE60126801D1/de
Publication of DE60126801T2 publication Critical patent/DE60126801T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60126801T 2000-10-25 2001-10-25 Lipidformulierungen zur zielgerichteten abgabe Expired - Lifetime DE60126801T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24318500P 2000-10-25 2000-10-25
US243185P 2000-10-25
PCT/CA2001/001513 WO2002034236A2 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Publications (2)

Publication Number Publication Date
DE60126801D1 true DE60126801D1 (de) 2007-04-05
DE60126801T2 DE60126801T2 (de) 2007-12-06

Family

ID=22917671

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126801T Expired - Lifetime DE60126801T2 (de) 2000-10-25 2001-10-25 Lipidformulierungen zur zielgerichteten abgabe

Country Status (7)

Country Link
EP (1) EP1328254B1 (de)
JP (1) JP2004511572A (de)
AT (1) ATE354350T1 (de)
AU (1) AU2002214854A1 (de)
CA (1) CA2426244A1 (de)
DE (1) DE60126801T2 (de)
WO (1) WO2002034236A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485031T1 (de) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
EP2567693B1 (de) * 2003-07-16 2015-10-21 Protiva Biotherapeutics Inc. Interferierende, in Lipiden eingekapselte RNA
MXPA06012722A (es) 2004-05-05 2007-02-14 Atugen Ag Lipidos, complejos de lipido y su uso.
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7807815B2 (en) 2004-07-02 2010-10-05 Protiva Biotherapeutics, Inc. Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
WO2006063411A2 (en) * 2004-12-16 2006-06-22 Protech Research Pty Ltd Transfer of molecules
AU2005316213C1 (en) * 2004-12-16 2011-08-25 Protech Research Pty Ltd Transfer of molecules
KR101366482B1 (ko) * 2004-12-27 2014-02-21 사일런스 테라퓨틱스 아게 코팅된 지질 복합체 및 이들의 용도
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2008009477A2 (en) 2006-07-21 2008-01-24 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
JP2010513354A (ja) 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
KR20100017928A (ko) * 2007-05-25 2010-02-16 더 유니버시티 오브 브리티쉬 콜롬비아 치료제의 경구 투여를 위한 제제 및 관련 방법
JP2011506432A (ja) * 2007-12-10 2011-03-03 エピターゲット・アーエス 非ラメラ形成脂質を含む音響感受性薬物送達粒子
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
CN102203618B (zh) 2008-10-30 2014-10-15 郭培宣 用于dna测序和其他用途的膜集成病毒dna包装马达蛋白连接器生物传感器
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767129C (en) 2009-07-01 2015-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2899155A1 (en) 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
EP4276176A3 (de) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna-therapie für argininosuccinat-synthase-mangel
EP3060258A1 (de) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna-therapie für phenylketonurie
JP6621409B2 (ja) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
CN108096189A (zh) * 2016-11-25 2018-06-01 国家纳米科学中心 一种脂质体纳米颗粒及其药物组合物和应用
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP4219715A3 (de) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
EP3775211B1 (de) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna kompositionen und methoden zu deren verwendung
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CN110638759A (zh) * 2019-10-29 2020-01-03 珠海丽凡达生物技术有限公司 一种用于体外转染和体内递送mRNA的制剂
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4314292A1 (de) 2021-03-26 2024-02-07 MiNA Therapeutics Limited Tmem173-sarna-zusammensetzungen und verfahren zur verwendung
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
DE69841002D1 (de) * 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
JP2001510808A (ja) * 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
WO2000062813A2 (en) * 1999-04-20 2000-10-26 The University Of British Columbia Cationic peg-lipids and methods of use

Also Published As

Publication number Publication date
EP1328254A2 (de) 2003-07-23
EP1328254B1 (de) 2007-02-21
DE60126801T2 (de) 2007-12-06
JP2004511572A (ja) 2004-04-15
WO2002034236A3 (en) 2003-01-09
CA2426244A1 (en) 2002-05-02
ATE354350T1 (de) 2007-03-15
WO2002034236A2 (en) 2002-05-02
AU2002214854A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
ATE354350T1 (de) Lipidformulierungen zur zielgerichteten abgabe
WO2006012502A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2003099830A3 (en) Cardiolipin compositions, methods of preparation and use
ATE537263T1 (de) Kationische lipide und verwendungsverfahren
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
EP1149115A4 (de) Verfahren zum hervorrufen von breit wirksamen, neutralisierenden antikörpern, die gegen gp41 von hiv-1 gerichtet sind.
WO2007028065A3 (en) Chimeric oligomeric compounds for modulation of splicing
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
WO2007111720A8 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
DE502004008588D1 (de) Agrochemische formulierungen
CR7616A (es) Profarmacos de aminoacidos excitadores
WO2006053250A3 (en) Lipase inhibitors
CY1107033T1 (el) Συνθεση στη μορφη σπρεϊ η οποια περιλαμβανει ενα συνδυασμο προπιονικης κλομπεταζολης και καλσιτριολης, μια αλκοολικη φαση και μια ελαιωδη φαση
WO2004067063A3 (en) Improved formulations for transmucosal vaginal delivery of bisphosphonates
WO2004096233A3 (en) Nucleoside phosphonate conjugates
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2002043773A3 (en) Tissue specific prodrugs
EA200401565A1 (ru) Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
WO2004045491A3 (en) Targeted double stranded rna mediated cell killing
WO2005069855A3 (en) Modulators of angiogenesis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition